Vintafolide in combination with pegylated liposomal doxorubicin hydrochloride for the treatment of folate receptor positive, platinum resistant ovarian cancer
 
Status Suspended
Decision Selected
Process STA pre-2018
Topic area
  • Cancer
  • Gynaecology, pregnancy and birth

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager:

TBC
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
Update: Date:
16 July 2014 The Institute has now been informed by the manufacturer that it has withdrawn its application for a conditional marketing authorisation for vintafolide in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual